Gasdermin E and neoplasms

doi:10.3760/cma.j.cn371439-20210520-00038

Abstract

Abstract:

Gasdermin E is closely related to neoplasms, which is involved in the occurrence and development of neoplasms through gene methylation, gene mutation or other ways. Pyroptosis mediated by gasdermin E is involved in drug therapy of various neoplasms, which provides a new theoretical basis for drug therapy of neoplasms. The study of gasdermin E aims to deepen the understanding of neoplasms and provide a new perspective for the prevention and treatment of neoplasms.

Key words: Pyroptosis, Neoplasms, Gasdermin E

Ma Meijie, Ma Huihan, Mi Jiaqing, Qin Qian, Feng Qinmei. Gasdermin E and neoplasms[J]. Journal of International Oncology, 2022, 49(4): 216-219.

References 31

[1]	Booth KT, Azaiez H, Smith RJH. DFNA5 (GSDME) c.991-15_991-13delTTC: founder mutation or mutational hotspot?[J]. Int J Mol Sci, 2020, 21(11): 3951. DOI: 10.3390/ijms21113951. doi: 10.3390/ijms21113951
[2]	Wang Y, Gao W, Shi X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature, 2017, 547(7661): 99-103. DOI: 10.1038/nature22393. doi: 10.1038/nature22393
[3]	Jorgensen I, Rayamajhi M, Miao EA. Programmed cell death as a defence against infection[J]. Nat Rev Immunol, 2017, 17(3): 151-164. DOI: 10.1038/nri.2016.147. doi: 10.1038/nri.2016.147 pmid: 28138137
[4]	Chen S, Mei S, Luo Y, et al. Gasdermin family: a promising therapeutic target for stroke[J]. Transl Stroke Res, 2018, 9(6): 555-563. DOI: 10.1007/s12975-018-0666-3. doi: 10.1007/s12975-018-0666-3
[5]	Qiu S, Liu J, Xing F. ‘Hints’ in the killer protein gasdermin D: unveiling the secrets of gasdermins driving cell death[J]. Cell Death Differ, 2017, 24(4): 588-596. DOI: 10.1038/cdd.2017.24. doi: 10.1038/cdd.2017.24
[6]	Chiang CY, Ching YH, Chang TY, et al. Novel eye genes systematically discovered through an integrated analysis of mouse transcriptomes and phenome[J]. Comput Struct Biotechnol J, 2019, 18: 73-82. DOI: 10.1016/j.csbj.2019.12.009. doi: 10.1016/j.csbj.2019.12.009
[7]	Stoll G, Ma Y, Yang H, et al. Pro-necrotic molecules impact local immunosurveillance in human breast cancer[J]. Oncoimmunology, 2017, 6(4): e1299302. DOI: 10.1080/2162402X.2017.1299302. doi: 10.1080/2162402X.2017.1299302
[8]	Guo M, An F, Yu H, et al. Comparative effects of schisandrin A, B, and C on Propionibacterium acnes-induced, NLRP3 inflammasome activation-mediated IL-1β secretion and pyroptosis[J]. Biomed Pharmacother, 2017, 96: 129-136. DOI: 10.1016/j.biopha.2017.09.097. doi: 10.1016/j.biopha.2017.09.097
[9]	Wang Y, Yin B, Li D, et al. GSDME mediates caspase-3-dependent pyroptosis in gastric cancer[J]. Biochem Biophys Res Commun, 2018, 495(1): 1418-1425. DOI: 10.1016/j.bbrc.2017.11.156. doi: 10.1016/j.bbrc.2017.11.156
[10]	Li Q, Chen L, Dong Z, et al. Piperlongumine analogue L50377 induces pyroptosis via ROS mediated NF-κB suppression in non-small-cell lung cancer[J]. Chem Biol Interact, 2019, 313: 108820. DOI: 10.1016/j.cbi.2019.108820. doi: 10.1016/j.cbi.2019.108820
[11]	Hu J, Dong Y, Ding L, et al. Local delivery of arsenic trioxide nanoparticles for hepatocellular carcinoma treatment[J]. Signal Transduct Target Ther, 2019, 4: 28. DOI: 10.1038/s41392-019-0062-9. doi: 10.1038/s41392-019-0062-9
[12]	Ding Q, Zhang W, Cheng C, et al. Dioscin inhibits the growth of human osteosarcoma by inducing G₂/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo[J]. J Cell Physiol, 2020, 235(3): 2911-2924. DOI: 10.1002/jcp.29197. doi: 10.1002/jcp.29197
[13]	Kong Y, Feng Z, Chen A, et al. The natural flavonoid galangin elicits apoptosis, pyroptosis, and autophagy in glioblastoma[J]. Front Oncol, 2019, 9: 942. DOI: 10.3389/fonc.2019.00942. doi: 10.3389/fonc.2019.00942
[14]	Kim MS, Lebron C, Nagpal JK, et al. Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer[J]. Biochem Biophys Res Commun, 2008, 370(1): 38-43. DOI: 10.1016/j.bbrc.2008.03.026. doi: 10.1016/j.bbrc.2008.03.026
[15]	Croes L, de Beeck KO, Pauwels P, et al. DFNA5 promoter me-thylation a marker for breast tumorigenesis[J]. Oncotarget, 2017, 8(19): 31948-31958. DOI: 10.18632/oncotarget.16654. doi: 10.18632/oncotarget.16654
[16]	Croes L, Beyens M, Fransen E, et al. Large-scale analysis of DFNA5 methylation reveals its potential as biomarker for breast cancer[J]. Clin Epigenetics, 2018, 10: 51. DOI: 10.1186/s13148-018-0479-y. doi: 10.1186/s13148-018-0479-y
[17]	Kim MS, Chang X, Yamashita K, et al. Aberrant promoter methy-lation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma[J]. Oncogene, 2008, 27(25): 3624-3634. DOI: 10.1038/sj.onc.1211021. doi: 10.1038/sj.onc.1211021 pmid: 18223688
[18]	Yokomizo K, Harada Y, Kijima K, et al. Methylation of the DFNA5 gene is frequently detected in colorectal cancer[J]. Anticancer Res, 2012, 32(4): 1319-1322. pmid: 22493364
[19]	Ibrahim J, Op de Beeck K, Fransen E, et al. Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer[J]. Cancer Med, 2019, 8(5): 2133-2145. DOI: 10.1002/cam4.2103. doi: 10.1002/cam4.2103
[20]	Croes L, Fransen E, Hylebos M, et al. Determination of the potential tumor-suppressive effects of GSDME in a chemically induced and in a genetically modified intestinal cancer mouse model[J]. Cancers (Basel), 2019, 11(8): 1214. DOI: 10.3390/cancers11081214. doi: 10.3390/cancers11081214
[21]	Akino K, Toyota M, Suzuki H, et al. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer[J]. Cancer Sci, 2007, 98(1): 88-95. DOI: 10.1111/j.1349-7006.2006.00351.x. doi: 10.1111/j.1349-7006.2006.00351.x.
[22]	Zhang Z, Zhang Y, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity[J]. Nature, 2020, 579(7799): 415-420. DOI: 10.1038/s41586-020-2071-9. doi: 10.1038/s41586-020-2071-9
[23]	Peng Z, Wang P, Song W, et al. GSDME enhances Cisplatin sensitivity to regress non-small cell lung carcinoma by mediating pyroptosis to trigger antitumor immunocyte infiltration[J]. Signal Transduct Target Ther, 2020, 5(1): 159. DOI: 10.1038/s41392-020-00274-9. doi: 10.1038/s41392-020-00274-9
[24]	Zhang CC, Li CG, Wang YF, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation[J]. Apoptosis, 2019, 24(3/4): 312-325. DOI: 10.1007/s10495-019-01515-1. doi: 10.1007/s10495-019-01515-1
[25]	Lu H, Zhang S, Wu J, et al. Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death[J]. Clin Cancer Res, 2018, 24(23): 6066-6077. DOI: 10.1158/1078-0432.CCR-18-1478. doi: 10.1158/1078-0432.CCR-18-1478
[26]	Chen L, Li Q, Zheng Z, et al. Design and optimize N-substituted EF24 as effective and low toxicity NF-κB inhibitor for lung cancer therapy via apoptosis-to-pyroptosis switch[J]. Chem Biol Drug Des, 2019, 94(1): 1368-1377. DOI: 10.1111/cbdd.13514. doi: 10.1111/cbdd.13514
[27]	Chen L, Weng B, Li H, et al. A thiopyran derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF-κB mediated apoptosis-to-pyroptosis switch[J]. Apoptosis, 2019, 24(1/2): 74-82. DOI: 10.1007/s10495-018-1499-y. doi: 10.1007/s10495-018-1499-y
[28]	Zhu M, Wang J, Xie J, et al. Design, synthesis, and evaluation of chalcone analogues incorporate α,β-unsaturated ketone functiona-lity as anti-lung cancer agents via evoking ROS to induce pyroptosis[J]. Eur J Med Chem, 2018, 157: 1395-1405. DOI: 10.1016/j.ejmech.2018.08.072. doi: 10.1016/j.ejmech.2018.08.072
[29]	Wu M, Wang Y, Yang D, et al. A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma[J]. EBioMedicine, 2019, 41: 244-255. DOI: 10.1016/j.ebiom.2019.02.012. doi: 10.1016/j.ebiom.2019.02.012
[30]	Zhou B, Zhang JY, Liu XS, et al. Tom20 senses iron-activated ROS signaling to promote melanoma cell pyroptosis[J]. Cell Res, 2018, 28(12): 1171-1185. DOI: 10.1038/s41422-018-0090-y. doi: 10.1038/s41422-018-0090-y pmid: 30287942
[31]	Yu J, Li S, Qi J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells[J]. Cell Death Dis, 2019, 10(3): 193. DOI: 10.1038/s41419-019-1441-4. doi: 10.1038/s41419-019-1441-4